 <h1>Neupro Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>rotigotine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about rotigotine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Neupro.</p><h2>In Summary</h2><p><b>Common side effects of Neupro include:</b> application site reaction, insomnia, nausea, and vomiting. <b>Other side effects include:</b> dizziness, dyspepsia, increased blood pressure, increased heart rate, orthostatic hypotension, and orthostatic dizziness.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to rotigotine: transdermal patch extended release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, rotigotine (the active ingredient contained in Neupro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking rotigotine:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, itching, redness, skin rash, swelling, or soreness at the application site</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody or cloudy urine</li>
<li>blurred vision or other changes in vision</li>
<li>difficult, burning, or painful urination</li>
<li>dizziness</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>lower back or side pain</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>slow or fast heartbeat</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking rotigotine:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Confusion</li>
<li>convulsions</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>nausea</li>
<li>sweating</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of rotigotine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Sleepiness or unusual drowsiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>difficulty having a bowel movement (stool)</li>
<li>difficulty with moving</li>
<li>dreaming abnormal</li>
<li>dry mouth</li>
<li>feeling of constant movement of self or surroundings</li>
<li>heartburn</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
<li>sensation of spinning</li>
<li>sleeplessness</li>
<li>stomach discomfort, upset, or pain</li>
<li>trouble sleeping</li>
<li>unable to sleep</li>
<li>weight loss</li>
</ul><p>
<!-- end transdermal patch extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rotigotine: transdermal film extended release</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 14%), orthostatic hypotension (up to 32%)</p>
<p><b>Common</b> (1% to 10%): Abnormal ECG T wave, first degree AV block, hypertension, palpitations</p>
<p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation</p>
<p><b>Rare</b> (less than 0.1%): Supraventricular tachycardia<sup>[Ref]</sup></p><p>The incidence of significant decreases in blood pressure or orthostatic hypotension increased during periods of dose escalation and titration.  In patients taking maximum recommended doses, orthostatic hypotension occurred (compared to placebo) at 29% (vs 11%), 27% (vs 23%), and 8% (vs 7%), in those with early stage Parkinson's disease (PD), advanced-stage PD, and restless legs syndrome, respectively.  </p>
<p></p>
<p>The incidence of peripheral edema was 3% and 2% for patients with early-stage PD compared with 9% and 1% for patients with advanced-stage PD receiving drug and placebo, respectively.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 41%), vomiting (up to 20%), </p>
<p><b>Common</b> (1% to 10%): Dyspepsia, constipation, diarrhea, dry mouth, </p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal pain<sup>[Ref]</sup></p><p>Nausea and vomiting may occur at the beginning of therapy but these are usually mild or moderate in intensity and transient even if treatment is continued.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>In clinical trials, 2% of patients receiving maximum doses of this drug for restless legs syndrome reported sleep attacks compared with 0% of patients receiving placebo.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Somnolence (up to 32%), dizziness (up to 23%), dyskinesia (up to 14%), headache (up to 21%)</p>
<p><b>Common</b> (1% to 10%): Balance disorder, paresthesia, tremor, hypoesthesia, sleep attacks</p>
<p><b>Rare</b> (less than 0.1%): Convulsion</p>
<p><b>Postmarketing reports</b>: Dropped head syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Muscle spasms</p>
<p><b>Frequency not reported</b>: Elevated creatine phosphokinase<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Sinus congestion, nasal congestion, cough, nasopharyngitis, hiccups<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Visual disturbances</p>
<p><b>Uncommon</b> (0.1% to 1%): Blurred vision, visual impairment, photopsia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): WBC in urine</p>
<p><b>Uncommon</b> (0.1% to 1%): Erectile dysfunction<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity including tongue edema and lip edema<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatic enzyme increases (ALT, AST, GGT)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia, increased weight, decreased weight</p>
<p><b>Frequency not reported</b>: Decreased serum glucose<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Elevated BUN<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Decreased serum ferritin</p>
<p><b>Frequency not reported</b>: Decreased hemoglobin/hematocrit<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Application site reactions (up to 46%), hyperhidrosis (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Erythema, pruritus, </p>
<p><b>Uncommon</b> (0.1% to 1%): Contact dermatitis</p>
<p><b>Rare</b> (less than 0.1%): Generalized rash<sup>[Ref]</sup></p><p>Application site reactions (ASRs) exhibited a dose-dependent relationship for all doses in patients with both Parkinson's disease and restless legs syndrome.  Reactions included localized erythema, edema, or pruritus, generally limited to the patch area; although generalized skin reactions such as allergic rash, including erythematous, macular-papular rash, or pruritus were reported at a lower incidence.  Rotation of application sites has been shown to reduce the incidence of ASRs.  </p>
<p></p>
<p>When applied as instructed, 34.2% (n=748) of patients experienced ASR; the majority were mild or moderate in intensity.  Discontinuation occurred in 7.2% of patients<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Disturbances in initiating and maintaining sleep (up to 14%), hallucinations (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Abnormal dreams, nightmare, irritability, sleep disorder, depression, impulse-control disorders </p>
<p><b>Uncommon</b> (0.1% to 1%): Obsessive-compulsive disorder, disorientation, agitation</p>
<p><b>Rare</b> (less than 0.1%): Aggressive behavior, binge eating, delusion, delirium<sup>[Ref]</sup></p><h3>Other</h3><p>Asthenic conditions included asthenia, malaise, and fatigue.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Fatigue (up to 18%), asthenic conditions (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Tinnitus, vertigo<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Menstrual disorder, sexual desire disorder<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions experienced among patients with Parkinson's disease included nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, disturbances in initiating and maintaining sleep, hyperhidrosis, visual disturbances, peripheral edema, and dyskinesia.  For patients with Restless Legs Syndrome, the most common adverse reactions included application site reactions, nausea, disturbances in initiating and maintaining sleep, somnolence, and headache.<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Basal cell carcinoma<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Neupro (rotigotine)." Schwarz Pharma, Mequon, WI. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Neupro (rotigotine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>55 Reviews</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Neupro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Restless Legs Syndrome</li>
<li>Parkinson's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to rotigotine: transdermal film extended release</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 14%), orthostatic hypotension (up to 32%)</p><p><b>Common</b> (1% to 10%): Abnormal ECG T wave, first degree AV block, hypertension, palpitations</p><p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation</p><p><b>Rare</b> (less than 0.1%): Supraventricular tachycardia<sup>[Ref]</sup></p><p>The incidence of significant decreases in blood pressure or orthostatic hypotension increased during periods of dose escalation and titration.  In patients taking maximum recommended doses, orthostatic hypotension occurred (compared to placebo) at 29% (vs 11%), 27% (vs 23%), and 8% (vs 7%), in those with early stage Parkinson's disease (PD), advanced-stage PD, and restless legs syndrome, respectively.  </p><p></p><p>The incidence of peripheral edema was 3% and 2% for patients with early-stage PD compared with 9% and 1% for patients with advanced-stage PD receiving drug and placebo, respectively.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 41%), vomiting (up to 20%), </p><p><b>Common</b> (1% to 10%): Dyspepsia, constipation, diarrhea, dry mouth, </p><p><b>Uncommon</b> (0.1% to 1%): Abdominal pain<sup>[Ref]</sup></p><p>Nausea and vomiting may occur at the beginning of therapy but these are usually mild or moderate in intensity and transient even if treatment is continued.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>In clinical trials, 2% of patients receiving maximum doses of this drug for restless legs syndrome reported sleep attacks compared with 0% of patients receiving placebo.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Somnolence (up to 32%), dizziness (up to 23%), dyskinesia (up to 14%), headache (up to 21%)</p><p><b>Common</b> (1% to 10%): Balance disorder, paresthesia, tremor, hypoesthesia, sleep attacks</p><p><b>Rare</b> (less than 0.1%): Convulsion</p><p><b>Postmarketing reports</b>: Dropped head syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 11%)</p><p><b>Common</b> (1% to 10%): Muscle spasms</p><p><b>Frequency not reported</b>: Elevated creatine phosphokinase<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Sinus congestion, nasal congestion, cough, nasopharyngitis, hiccups<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Visual disturbances</p><p><b>Uncommon</b> (0.1% to 1%): Blurred vision, visual impairment, photopsia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): WBC in urine</p><p><b>Uncommon</b> (0.1% to 1%): Erectile dysfunction<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity including tongue edema and lip edema<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatic enzyme increases (ALT, AST, GGT)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia, increased weight, decreased weight</p><p><b>Frequency not reported</b>: Decreased serum glucose<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Elevated BUN<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Decreased serum ferritin</p><p><b>Frequency not reported</b>: Decreased hemoglobin/hematocrit<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Application site reactions (up to 46%), hyperhidrosis (up to 11%)</p><p><b>Common</b> (1% to 10%): Erythema, pruritus, </p><p><b>Uncommon</b> (0.1% to 1%): Contact dermatitis</p><p><b>Rare</b> (less than 0.1%): Generalized rash<sup>[Ref]</sup></p><p>Application site reactions (ASRs) exhibited a dose-dependent relationship for all doses in patients with both Parkinson's disease and restless legs syndrome.  Reactions included localized erythema, edema, or pruritus, generally limited to the patch area; although generalized skin reactions such as allergic rash, including erythematous, macular-papular rash, or pruritus were reported at a lower incidence.  Rotation of application sites has been shown to reduce the incidence of ASRs.  </p><p></p><p>When applied as instructed, 34.2% (n=748) of patients experienced ASR; the majority were mild or moderate in intensity.  Discontinuation occurred in 7.2% of patients<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Disturbances in initiating and maintaining sleep (up to 14%), hallucinations (up to 13%)</p><p><b>Common</b> (1% to 10%): Abnormal dreams, nightmare, irritability, sleep disorder, depression, impulse-control disorders </p><p><b>Uncommon</b> (0.1% to 1%): Obsessive-compulsive disorder, disorientation, agitation</p><p><b>Rare</b> (less than 0.1%): Aggressive behavior, binge eating, delusion, delirium<sup>[Ref]</sup></p><h3>Other</h3><p>Asthenic conditions included asthenia, malaise, and fatigue.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Fatigue (up to 18%), asthenic conditions (up to 14%)</p><p><b>Common</b> (1% to 10%): Tinnitus, vertigo<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Menstrual disorder, sexual desire disorder<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions experienced among patients with Parkinson's disease included nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, disturbances in initiating and maintaining sleep, hyperhidrosis, visual disturbances, peripheral edema, and dyskinesia.  For patients with Restless Legs Syndrome, the most common adverse reactions included application site reactions, nausea, disturbances in initiating and maintaining sleep, somnolence, and headache.<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Basal cell carcinoma<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Neupro (rotigotine)." Schwarz Pharma, Mequon, WI. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Neupro (rotigotine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>55 Reviews</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Neupro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Restless Legs Syndrome</li>
<li>Parkinson's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>